Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017


  • Products Id :- GDHC4781CTIDB
  • |
  • Pages: 1674
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, "Metastatic Breast Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Metastatic Breast Cancer to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Metastatic Breast Cancer Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Metastatic Breast Cancer

Dec 08, 2017: Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer

Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium

Dec 07, 2017: Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival

Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)

Dec 05, 2017: Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Dec 05, 2017: New Scientific Publication Supports Agilvax's Novel Immunotherapy Development for Metastatic Breast Cancer

Dec 04, 2017: Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression

Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit

Nov 30, 2017: New and Updated Data for Merck's KEYTRUDA (pembrolizumab) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)

Nov 30, 2017: Updated Data on LYNPARZA (olaparib) in Multiple Breast Cancer Subtypes to be Presented at the 2017 San Antonio Breast Cancer Symposium (SABCS)

Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS

Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium

Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer

Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017

Nov 06, 2017: Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer

Oct 31, 2017: Dr. Frdric Triebel Presented at the World Immunotherapy Congress 2017

Oct 31, 2017: Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain

Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oct 19, 2017: BerGenBio Announces Start of Phase II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer

Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum

Oct 06, 2017: Lilly MONARCH 3 Study Published In Journal Of Clinical Oncology Demonstrates Benefit Of Verzenio (Abemaciclib) Plus NSAI In Advanced Breast Cancer

Oct 05, 2017: Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin

Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program

Sep 22, 2017: Eisai Presents Latest Non-Clinical Data On Its First Antibody-Drug Conjugate MORAb-202 At 8th Annual World ADC

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Disclaimer

Source

List of Figures

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017*

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017*

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016

Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

GlobalData Methodology

List of Tables

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2017*

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*

Metastatic Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*

Proportion of Metastatic Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2017*

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*

Metastatic Breast Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017*

Metastatic Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016

Metastatic Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*

Metastatic Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd

Novartis AG

Pfizer Inc

AstraZeneca Plc

GlaxoSmithKline Plc

Eli Lilly and Co

Sarah Cannon Research Institute LLC

Merck & Co Inc

Sanofi

Bristol-Myers Squibb Co

select a license

Single User License
USD 2500 INR 179700
Site License
USD 5000 INR 359400
Corporate User License
USD 7500 INR 539100

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com